{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:20:27Z","timestamp":1795044027733,"version":"4.10.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01319-7","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:00:41Z","timestamp":1791831641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based Biopharmaceutics Modeling (PBBM) Reveals a Low Dissolution-related Bioequivalence Risk for Immediate-Release Amlodipine Tablets"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-5819","authenticated-orcid":false,"given":"Porfirio","family":"de la Cruz Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1843-0602","authenticated-orcid":false,"given":"Larissa Lopes Rodrigues","family":"Gomide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4476-0047","authenticated-orcid":false,"given":"Gabriela Moraes","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-0033","authenticated-orcid":false,"given":"Jos\u00e9 Trinidad P\u00e9rez","family":"Urizar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7503-2328","authenticated-orcid":false,"given":"Alberto Mart\u00ednez","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-8303","authenticated-orcid":false,"given":"\u00c1ngel Antonio V\u00e9rtiz","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2314-8465","authenticated-orcid":false,"given":"Amaury","family":"de Jes\u00fas Pozos Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-7888","authenticated-orcid":false,"given":"H\u00e9ctor Eduardo Flores","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-2876","authenticated-orcid":false,"given":"Ricardo Zamora","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4096-4919","authenticated-orcid":false,"given":"Luis Manuel Romero","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0056-1916","authenticated-orcid":false,"given":"Marcelino Garc\u00eda","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5618-3318","authenticated-orcid":false,"given":"Mauricio A.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-3687","authenticated-orcid":false,"given":"Michele Georges","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-9862","authenticated-orcid":false,"given":"Marcelo Dutra","family":"Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"1319_CR1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0252-3","author":"S Suarez-Sharp","year":"2018","unstructured":"Suarez-Sharp S, Cohen M, Kesisoglou F, Abend A, Marroum P, Delvadia P, et al. Applications of clinically relevant dissolution testing: workshop summary report. AAPS J. 2018. https:\/\/doi.org\/10.1208\/s12248-018-0252-3.","journal-title":"AAPS J"},{"key":"1319_CR2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0298-x","author":"T Heimbach","year":"2019","unstructured":"Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, et al. Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link\u2014a workshop summary report. AAPS J. 2019. https:\/\/doi.org\/10.1208\/s12248-019-0298-x.","journal-title":"AAPS J"},{"key":"1319_CR3","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00202","author":"C Mackie","year":"2023","unstructured":"Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, et al. Physiologically based biopharmaceutics modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report. Mol Pharm. 2023. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00202.","journal-title":"Mol Pharm"},{"key":"1319_CR4","unstructured":"FDA. Center for Drug Evaluation and Research (CDER). Norvasc (amlodipine besylate) tablets label [Internet]. 2011. Available from: https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=562. Accessed 7 Oct 2025."},{"key":"1319_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(89)90834-x","author":"D Abernethy","year":"1989","unstructured":"Abernethy D. The pharmacokinetic profile of amlodipine. Am Heart J. 1989. https:\/\/doi.org\/10.1016\/0002-8703(89)90834-x.","journal-title":"Am Heart J"},{"issue":"9","key":"1319_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.4314\/tjpr.v17i9.1","volume":"17","author":"H Jung-Cook","year":"2018","unstructured":"Jung-Cook H, Mayet-Cruz L, Girard-Cuesy ME. Comparative in vitro dissolution and in vivo bioavailability of commercial amlodipine tablets. Trop J Pharm Res. 2018;17(9):1685\u201391. https:\/\/doi.org\/10.4314\/tjpr.v17i9.1.","journal-title":"Trop J Pharm Res"},{"key":"1319_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.104108","author":"P de la Cruz-Cruz","year":"2025","unstructured":"de la Cruz-Cruz P, Garc\u00eda MA, P\u00e9rez-Urizar JT, Abrahamsson B, Cristofoletti R, Kambayashi A, et al. Biowaiver monograph for immediate-release solid oral dosage forms: amlodipine besylate. J Pharm Sci. 2025. https:\/\/doi.org\/10.1016\/j.xphs.2025.104108.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1319_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/psp4.12634","volume":"10","author":"JS Macwan","year":"2021","unstructured":"Macwan JS, Fraczkiewicz G, Bertolino M, Kr\u00fcger P, Peters SA. Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: the case of bisoprolol. CPT Pharmacomet Syst Pharmacol. 2021;10(6):622\u201332. https:\/\/doi.org\/10.1002\/psp4.12634.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1319_CR9","doi-asserted-by":"publisher","DOI":"10.5414\/CP202449","author":"AC van der Vossen","year":"2016","unstructured":"van der Vossen AC, der Velde IV, van der Nagel BCH, Koch BCP, Vulto AG, Hanff LM. Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. Int J Clin Pharmacol Ther. 2016. https:\/\/doi.org\/10.5414\/CP202449.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"1319_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1211\/jpp.58.6.0013","volume":"58","author":"D Rau\u0161l","year":"2006","unstructured":"Rau\u0161l D, Fotaki N, Zano\u0161ki R, Vertzoni M, Cetina-\u010ci\u017emek B, Khan MZI, et al. Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. J Pharm Pharmacol. 2006;58(6):827\u201336. https:\/\/doi.org\/10.1211\/jpp.58.6.0013.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"1319_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1124\/dmd.112.050054","volume":"41","author":"F Kazmi","year":"2013","unstructured":"Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41(4):897\u2013905. https:\/\/doi.org\/10.1124\/dmd.112.050054.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1319_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.xphs.2018.09.036","volume":"108","author":"MB Bolger","year":"2019","unstructured":"Bolger MB, Macwan JS, Sarfraz M, Almukainzi M, L\u00f6benberg R. The irrelevance of in vitro dissolution in setting product specifications for drugs like dextromethorphan that are subject to lysosomal trapping. J Pharm Sci. 2019;108(1):268\u201378. https:\/\/doi.org\/10.1016\/j.xphs.2018.09.036.","journal-title":"J Pharm Sci"},{"key":"1319_CR13","doi-asserted-by":"publisher","unstructured":"Vaiano-Carapeto G, Dutra-Duque M, Georges-Issa M, Gomes-Ferraz H. Development of biopredictive dissolution method for extended-release desvenlafaxine tablets. Pharmaceutics. 2023;15(5). https:\/\/doi.org\/10.3390\/pharmaceutics15051544.","DOI":"10.3390\/pharmaceutics15051544"},{"issue":"12","key":"1319_CR14","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1016\/j.xphs.2023.07.012","volume":"112","author":"E Miranda dos Santos","year":"2023","unstructured":"Miranda dos Santos E, Ferraz HG, Issa MG, Duque MD. Development of extended-release formulations containing cyclobenzaprine based on physiologically based biopharmaceutics modeling and bioequivalence safe space. J Pharm Sci. 2023;112(12):3131\u201340. https:\/\/doi.org\/10.1016\/j.xphs.2023.07.012.","journal-title":"J Pharm Sci"},{"key":"1319_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1177\/009286159603000427","volume":"30","author":"YI Tsong","year":"1996","unstructured":"Tsong YI, Hammerstrom T, Sathe P, Shah VP. Statistical assessment of mean differences between two dissolution data sets. Drug Inf J. 1996;30:1105\u201312. https:\/\/doi.org\/10.1177\/009286159603000427.","journal-title":"Drug Inf J"},{"key":"1319_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/204925","author":"J Zuo","year":"2014","unstructured":"Zuo J, Gao Y, Bou-Chacra N, L\u00f6benberg R. Evaluation of the DDSolver software applications. BioMed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/204925.","journal-title":"BioMed Res Int"},{"issue":"6","key":"1319_CR17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1023\/A:1011976615750","volume":"15","author":"VP Shah","year":"1998","unstructured":"Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison\u2014statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889\u201396. https:\/\/doi.org\/10.1023\/A:1011976615750.","journal-title":"Pharm Res"},{"issue":"6","key":"1319_CR18","first-page":"64","volume":"20","author":"JW Moore","year":"1996","unstructured":"Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20(6):64\u201374.","journal-title":"Pharm Technol"},{"key":"1319_CR19","unstructured":"Secretar\u00eda de Salud de M\u00e9xico. NORMA Oficial Mexicana NOM-177-SSA1\u20132013, Que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los Terceros Autorizados que realicen las pruebas de intercambiabilidad. Requisitos para realizar los estudios de biocomparabilidad. Requisitos a que deben sujetarse los Terceros Autorizados, Centros de Investigaci\u00f3n o Instituciones Hospitalarias que realicen las pruebas de biocomparabilidad. 2013. Available from: https:\/\/www.dof.gob.mx\/nota_detalle.php?codigo=5314833&fecha=20\/09\/2013#gsc.tab=0. Accessed 17 Oct 2025."},{"key":"1319_CR20","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use. Ich harmonised guideline biopharmaceutics classification system-based biowaivers M9 [Internet]. 2019. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/database.ich.org\/sites\/default\/files\/M9_Guideline_Step4_2019_1116.pdf. Accessed 17 Oct 2025."},{"issue":"6","key":"1319_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1023\/A:1011976615750","volume":"15","author":"VP Shah","year":"1998","unstructured":"Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison- statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889\u201396. https:\/\/doi.org\/10.1023\/A:1011976615750.","journal-title":"Pharm Res"},{"issue":"23","key":"1319_CR22","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1016\/j.bmc.2004.09.004","volume":"12","author":"G Caron","year":"2004","unstructured":"Caron G, Ermondi G, Damiano A, Novaroli L, Tsinman O, Ruell JA, et al. Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine. Bioorg Med Chem. 2004;12(23):6107\u201318. https:\/\/doi.org\/10.1016\/j.bmc.2004.09.004.","journal-title":"Bioorg Med Chem"},{"key":"1319_CR23","unstructured":"Giorgetti L. Desenvolvimento e caracteriza\u00e7\u00e3o de minicomprimidos contendo besilato de anlodipino [Internet]. UNIVERSIDADE DE S\u00c3O PAULO; 2012. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/teses.usp.br\/teses\/disponiveis\/9\/9139\/tde-01102013-111726\/publico\/Dissertacao_Leandro_Giorgetti.pdf. Accessed 17 Oct 2025."},{"key":"1319_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198812007-00012","author":"DA Stopher","year":"1988","unstructured":"Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol. 1988. https:\/\/doi.org\/10.1097\/00005344-198812007-00012.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1319_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","volume":"22","author":"JK Faulkner","year":"1986","unstructured":"Faulkner JK, Mcgibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22(1):21\u20135. https:\/\/doi.org\/10.1111\/j.1365-2125.1986.tb02874.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1319_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/a-0611-4927","volume":"68","author":"AN Zaid","year":"2018","unstructured":"Zaid AN, Shraim N, Radwan A, Jaradat N, Hirzallah S, Issa I, et al. Does GastroPlus support similarity and dissimilarity factors of in vitro-in vivo prediction in biowaiver studies? A lower strength amlodipine as a model drug. Drug Res. 2018;68(11):625\u201330. https:\/\/doi.org\/10.1055\/a-0611-4927.","journal-title":"Drug Res"},{"issue":"5","key":"1319_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jpha.2012.03.008","volume":"2","author":"VB Ravi","year":"2012","unstructured":"Ravi VB, Inamadugu JK, Pilli NR, Sreenivasulu V, Ponneri V. Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS\/MS and its application in a human pharmacokinetic study. J Pharm Anal. 2012;2(5):319\u201326. https:\/\/doi.org\/10.1016\/j.jpha.2012.03.008.","journal-title":"J Pharm Anal"},{"key":"1319_CR28","doi-asserted-by":"publisher","unstructured":"Kollipara S, Martins-Severino F, Jereb R, Krajcar D, Ahmed T. Advancing virtual bioequivalence for orally administered drug products: methodology, real-world applications and future outlook. Pharmaceuticals. 2024;17(7). https:\/\/doi.org\/10.3390\/ph17070876.","DOI":"10.3390\/ph17070876"},{"issue":"11","key":"1319_CR29","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1021\/acs.molpharmaceut.4c00758","volume":"21","author":"T Heimbach","year":"2024","unstructured":"Heimbach T, Musuamba Tshinanu F, Raines K, Borges L, Kijima S, Malamatari M, et al. PBBM considerations for base models, model validation, and application steps: workshop summary report. Mol Pharm. 2024;21(11):5353\u201372. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00758.","journal-title":"Mol Pharm"},{"key":"1319_CR30","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use. Ich harmonised guideline bioequivalence for immediaterelease solid oral dosage forms M13A [Internet]. 2024. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/database.ich.org\/sites\/default\/files\/ICH_M13A_Step4_Final_Guideline_2024_0723.pdf. Accessed 17 Oct 2025."},{"issue":"11","key":"1319_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/j.1552-4604.1988.tb03119.x","volume":"28","author":"DM Williams","year":"1988","unstructured":"Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1988;28(11):990\u20134. https:\/\/doi.org\/10.1002\/j.1552-4604.1988.tb03119.x.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1319_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/FJC.0b013e3181fc45bb","volume":"56","author":"FHH Leenen","year":"2010","unstructured":"Leenen FHH, Coletta E. Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. J Cardiovasc Pharmacol. 2010;56(6):669\u201375. https:\/\/doi.org\/10.1097\/FJC.0b013e3181fc45bb.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1319_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23228","author":"T Wang","year":"2020","unstructured":"Wang T, Wang Y, Lin S, Fang L, Lou S, Zhao D, et al. Evaluation of pharmacokinetics and safety with bioequivalence of amlodipine in healthy Chinese volunteers: bioequivalence study findings. J Clin Lab Anal. 2020. https:\/\/doi.org\/10.1002\/jcla.23228.","journal-title":"J Clin Lab Anal"},{"key":"1319_CR34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00283.x","author":"J Vincent","year":"2000","unstructured":"Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol. 2000. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00283.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1319_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102997","author":"C Quentin","year":"2021","unstructured":"Quentin C, Gerasimait\u0117 R, Freidzon A, Atabekyan LS, Lukinavi\u010dius G, Belov VN, et al. Direct visualization of amlodipine intervention into living cells by means of fluorescence microscopy. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26102997.","journal-title":"Molecules"},{"issue":"6","key":"1319_CR36","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1021\/acs.molpharmaceut.5c00225","volume":"22","author":"S Arora","year":"2025","unstructured":"Arora S, Pepin X, Jamei M, Sharma P, Heimbach T, Wagner C, et al. Development of a physiologically based biopharmaceutics model report template: considerations for improved quality in view of regulatory submissions. Mol Pharm. 2025;22(6):2735\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00225.","journal-title":"Mol Pharm"},{"key":"1319_CR37","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00764","author":"MA Garc\u00eda","year":"2024","unstructured":"Garc\u00eda MA, Paulos C, Ibarra Vi\u00f1ales M, Michelet R, \u00c1ngel Cabrera-P\u00e9rez M, Aceituno A, et al. Modelling and simulations in Latin-American generic markets: perspectives from Chilean local industry, regulatory agency and academia. Mol Pharm. 2024. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00764.","journal-title":"Mol Pharm"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01319-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:14:37Z","timestamp":1795043677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01319-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01319-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. Some authors are affiliated with FS SCIENTIA PHARMA S.A. de C.V. and Ultra Laboratorios S.A. de C.V., which provided technical support and access to facilities. However, these contributions did not influence the study design, data analysis, interpretation of results, or the decision to publish.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"169"}}